Jefferies Group LLC Analysts Give Aclaris Therapeutics Inc (ACRS) a $36.00 Price Target

Jefferies Group LLC set a $36.00 target price on Aclaris Therapeutics Inc (NASDAQ:ACRS) in a research report sent to investors on Thursday. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on the stock. Leerink Swann started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, November 29th. They issued an outperform rating for the company. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a hold rating to a buy rating and set a $35.00 price objective on the stock in a research note on Wednesday, March 1st. Finally, Guggenheim lifted their price objective on shares of Aclaris Therapeutics from $35.00 to $40.00 and gave the company a buy rating in a research note on Wednesday, March 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $36.25.

Aclaris Therapeutics (NASDAQ:ACRS) opened at 28.88 on Thursday. Aclaris Therapeutics has a 52-week low of $14.12 and a 52-week high of $33.25. The company has a 50 day moving average price of $28.79 and a 200 day moving average price of $26.33. The firm’s market capitalization is $618.96 million.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, March 15th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.10. On average, equities analysts forecast that Aclaris Therapeutics will post ($3.11) EPS for the current fiscal year.

var userip;Your IP Address: document.write(userip);

In other Aclaris Therapeutics news, Director Anand Mehra sold 750,000 shares of Aclaris Therapeutics stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $28.25, for a total value of $21,187,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total transaction of $13,098,500.00. The disclosure for this sale can be found here. Insiders own 46.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd acquired a new position in Aclaris Therapeutics during the fourth quarter worth approximately $209,000. Strs Ohio raised its position in shares of Aclaris Therapeutics by 170.0% in the third quarter. Strs Ohio now owns 8,100 shares of the company’s stock worth $207,000 after buying an additional 5,100 shares during the period. Citadel Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the third quarter worth about $238,000. Boothbay Fund Management LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $264,000. Finally, A.R.T. Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $325,000. Institutional investors own 61.94% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

5 Day Chart for NASDAQ:ACRS

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Teen Girls Barred from United Airlines Flight for Wearing Leggings
Teen Girls Barred from United Airlines Flight for Wearing Leggings
Fuel Shortage in Venezuela Growing Worse
Fuel Shortage in Venezuela Growing Worse
FedEx Comes Up Short on Earnings
FedEx Comes Up Short on Earnings
Brazil Looks to Calm Fears Over Export and Sale of Meat
Brazil Looks to Calm Fears Over Export and Sale of Meat
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram


Leave a Reply

© 2006-2017 Ticker Report. Google+.